Data as of .
IDNA vs PBE: which is really different?
IDNA and PBE hold 17% of their weight in the same names, and IDNA returned more over the year.
ETFIQ Off-Index Score: IDNA scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
17% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, IDNA and PBE hold 17% of their money in the same securities at the same weight.
| Holding | IDNA | PBE |
|---|---|---|
| REGENERON PHARMACEUTICALS | 3.63% | 4.89% |
| VERTEX PHARMACEUTICALS | 3.34% | 4.77% |
| EXELIXIS INC | 3.25% | 2.91% |
| MODERNA | 9.54% | 2.75% |
| INCYTE CORP | 3.60% | 2.73% |
| NOVAVAX | 1.46% | 3.03% |
| USD CASH | 0.06% | 0.00% |
| Only in IDNA | Only in PBE |
|---|---|
| TWIST BIOSCIENCE 7.09% | Natera Inc 5.70% |
| GENMAB 4.13% | Illumina Inc 5.53% |
| BAYER AG 3.87% | Gilead Sciences Inc 5.27% |
| REVOLUTION MEDICINES 3.76% | Biogen Inc 5.07% |
| IOVANCE BIOTHERAPEUTICS INC 3.67% | Royalty Pharma PLC 4.88% |
| TAKEDA PHARMACEUTICAL 3.62% | Amgen Inc 4.53% |
| MERCK & CO INC 3.57% | Sarepta Therapeutics Inc 3.01% |
| CARIS LIFE SCIENCES 3.39% | Halozyme Therapeutics Inc 2.91% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 19, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| IDNA | PBE | IDNA | PBE | IDNA | PBE | |
| 3 months | +30.3% | +13.2% | +28.1 pts | +11.0 pts | +32.8 pts | +15.7 pts |
| 6 months | +41.4% | +25.9% | +23.4 pts | +7.8 pts | +17.2 pts | +1.6 pts |
| 1 year | +73.4% | +36.2% | +56.9 pts | +19.6 pts | +51.7 pts | +14.4 pts |
| 3 years | +91.3% | +65.0% | +12.9 pts | −13.4 pts | −6.9 pts | −33.1 pts |
| Since launch | +69.7% | +492.4% | −123.9 pts | −311.1 pts | −242.0 pts | −1197.8 pts |
| IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | PBE Invesco Biotechnology & Genome ETF Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | iShares | Invesco |
| Theme | Genomics and gene editing | Biotech |
| In the S&P 500 | 23.9% | 30.0% |
| Active share vs the S&P 500 | 99.1% | 99.0% |
| In the Nasdaq-100 | 7.0% | 19.5% |
| Holdings | 62 | 33 |
| Top ten, share of the fund | 46.2% | 46.7% |
| Expense ratio | 0.47% | 0.59% |
| Fee for the differing part | 0.47% | 0.60% |
| Total return, 1 year | +73.4% | +36.2% |
| vs the S&P 500 | +56.9 pts | +19.6 pts |
| vs the Nasdaq-100 | +51.7 pts | +14.4 pts |
| Below its high | −24.7% | −3.9% |
| Net assets | $271m | $414m |
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
PBE in plain words
By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.
Questions people ask
- Do IDNA and PBE hold the same stocks?
- By their latest filings, 17% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, IDNA or PBE?
- IDNA has 24% of its weight in S&P 500 names and PBE has 30%, so IDNA differs more from the index.
- Which is cheaper, IDNA or PBE?
- IDNA charges 0.47% a year and PBE charges 0.59%, so IDNA is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IDNA against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/idna-vs-pbe Free to use with attribution; the underlying files are at Open data.